Imaging biomarkers in the idiopathic inflammatory myopathies by Adeel S. Zubair, Sharfaraz Salam, Mazen M. Dimachkie, Pedro M. Machado, Pedro M. Machado, Bhaskar Roy

Get full text

Conducting a bayesian multi-armed trial with response adaptive randomization for comparative effectiveness of medications for CSPN by Alexandra R. Brown, Byron J. Gajewski, Dinesh Pal Mudaranthakam, Mamatha Pasnoor, Mazen M. Dimachkie, Omar Jawdat, Laura Herbelin, Matthew S. Mayo, Richard J. Barohn

Get full text

Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease by Matthias Boentert, Kenneth I. Berger, Jordi Díaz-Manera, Mazen M. Dimachkie, Alaa Hamed, Lionel Riou França, Nathan Thibault, Pragya Shukla, Jack Ishak, J. Jaime Caro

Get full text

Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study by Rohit Aggarwal, Joachim Schessl, Christina Charles-Schoeman, Zsuzsanna Bata-Csörgő, Mazen M. Dimachkie, Zoltan Griger, Sergey Moiseev, Chester V. Oddis, Elena Schiopu, Jiri Vencovský, Irene Beckmann, Elisabeth Clodi, Todd Levine, the ProDERM investigators

Get full text

Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis by Chester V. Oddis, Howard E. Rockette, Lei Zhu, Diane C. Koontz, David Lacomis, Swamy Venturupalli, Siamak Moghadam‐Kia, Dana P. Ascherman, Leslie Crofford, Mazen M. Dimachkie, Floranne Ernste, David Gazeley, Galina Marder, Rohit Aggarwal

Get full text

Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease by Priya S. Kishnani, Barry J. Byrne, Kristl G. Claeys, Jordi Díaz-Manera, Mazen M. Dimachkie, Hani Kushlaf, Tahseen Mozaffar, Mark Roberts, Benedikt Schoser, Noemi Hummel, Agnieszka Kopiec, Fred Holdbrook, Simon Shohet, Antonio Toscano, on behalf of the PROPEL Study Group

Get full text

3024 COMET post hoc analysis: efficacy of long-term avalglucosidase alfa in subgroups of patients with late-onset Pompe disease by Mark Roberts, Jordi Diaz-Manera, Antonio Toscano, Sabrina Sacconi, Mazen M Dimachkie, Nicole Armstrong, Robert Henderson, Benedikt Schoser, Priya S Kishnani, Olivier Huynh-Ba, Nathan Thibault, Young Chul Choi, Shugo Suwazono, Paulo Victor Sgobbi de Souza, Magali Periquet

Resistance exercise in early-stage ALS patients, ALSFRS-R, Sickness Impact Profile ALS-19, and muscle transcriptome: a pilot study by Omar Jawdat, Jason Rucker, Tomoki Nakano, Kotaro Takeno, Jeffery Statland, Mamatha Pasnoor, Mazen M. Dimachkie, Carla Sabus, Yomna Badawi, Suzanne L. Hunt, Naoko H. Tomioka, Sumedha Gunewardena, Clark Bloomer, Heather M. Wilkins, Laura Herbelin, Richard J. Barohn, Hiroshi Nishimune

Get full text

Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America by Joel Oger, Joshua D Green, Bryan J Traynor, Richard J Barohn, Michael Benatar, Emanuela Bartoccion, Derrick Blackmore, Vinay Chaudhry, Manisha Chopra, Andrea Corse, Mazen M Dimachkie, Amelia Evoli, Julaine Florence, Miriam Freimer, James F Howard, Theresa Jiwa, Henry J Kaminski, John T Kissel, Wilma J Koopman, Bernadette Lipscomb, Michelanglo Maestri, Mariapaola Marino, Janice M Massey, April McVey, Michelle M Mezei, Srikanth Muppidi, Michael W Nicolle, Robert M Pascuzzi, Mamatha Pasnoor, Alan Pestronk, Carlo Provenzano, Roberta Ricciardi, David P Richman, Julie Rowin, Donald B Sanders, Zaeem Siddiqi, Aimee Soloway, Gil I Wolfe, Charlie Wulf, Daniel B Drachman

Get full text